Frontiers in Immunology (Feb 2024)

Adjuvant therapy provides no additional recurrence-free benefit for esophageal squamous cell carcinoma patients after neoadjuvant chemoimmunotherapy and surgery: a multi-center propensity score match study

  • Shu-Han Xie,
  • Shu-Han Xie,
  • Li-Tao Yang,
  • Li-Tao Yang,
  • Li-Tao Yang,
  • Hai Zhang,
  • Hai Zhang,
  • Hai Zhang,
  • Zi-Lu Tang,
  • Zi-Lu Tang,
  • Zhi-Wei Lin,
  • Zhi-Wei Lin,
  • Yi Chen,
  • Yi Chen,
  • Zhi-Nuan Hong,
  • Zhi-Nuan Hong,
  • Zhi-Nuan Hong,
  • Zhi-Nuan Hong,
  • Rong-Yu Xu,
  • Rong-Yu Xu,
  • Wan-Li Lin,
  • Ming-Qiang Kang,
  • Ming-Qiang Kang,
  • Ming-Qiang Kang,
  • Ming-Qiang Kang

DOI
https://doi.org/10.3389/fimmu.2024.1332492
Journal volume & issue
Vol. 15

Abstract

Read online

PurposeThe need for adjuvant therapy (AT) following neoadjuvant chemoimmunotherapy (nICT) and surgery in esophageal squamous cell cancer (ESCC) remains uncertain. This study aims to investigate whether AT offers additional benefits in terms of recurrence-free survival (RFS) for ESCC patients after nICT and surgery.MethodsRetrospective analysis was conducted between January 2019 and December 2022 from three centers. Eligible patients were divided into two groups: the AT group and the non-AT group. Survival analyses comparing different modalities of AT (including adjuvant chemotherapy and adjuvant chemoimmunotherapy) with non-AT were performed. The primary endpoint was RFS. Propensity score matching(PSM) was used to mitigate inter-group patient heterogeneity. Kaplan-Meier survival curves and Cox regression analysis were employed for recurrence-free survival analysis.ResultsA total of 155 nICT patients were included, with 26 patients experiencing recurrence. According to Cox analysis, receipt of adjuvant therapy emerged as an independent risk factor(HR:2.621, 95%CI:[1.089,6.310], P=0.032), and there was statistically significant difference in the Kaplan-Meier survival curves between non-AT and receipt of AT in matched pairs (p=0.026). Stratified analysis revealed AT bring no survival benefit to patients with pathological complete response(p= 0.149) and residual tumor cell(p=0.062). Subgroup analysis showed no significant difference in recurrence-free survival between non-AT and adjuvant chemoimmunotherapy patients(P=0.108). However, patients receiving adjuvant chemotherapy exhibited poorer recurrence survival compared to non-AT patients (p= 0.016).ConclusionIn terms of recurrence-free survival for ESCC patients after nICT and surgery, the necessity of adjuvant therapy especially the adjuvant chemotherapy, can be mitigated.

Keywords